December 10, 2015—The Senate Special Committee on Aging kicked off a series of hearings about drug price inflation yesterday with a session on skyrocketing prices for off-patent drugs lacking competition.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)